We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EKF Ekf Diagnostics Holdings Plc

0.00 (0.00%)
Last Updated: 08:00:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 26.95 26.80 28.70 - 4 08:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -12.14 122.6M
Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 26.95p. Over the last year, Ekf Diagnostics shares have traded in a share price range of 22.50p to 37.50p.

Ekf Diagnostics currently has 454,930,564 shares in issue. The market capitalisation of Ekf Diagnostics is £122.60 million. Ekf Diagnostics has a price to earnings ratio (PE ratio) of -12.14.

Ekf Diagnostics Share Discussion Threads

Showing 4326 to 4346 of 4800 messages
Chat Pages: Latest  180  179  178  177  176  175  174  173  172  171  170  169  Older
Chart is indeed conducive. Assuming wider markets play ball (big ask in the context of wider macro worries), this is indeed a good risk ward proposition on the long side ( for a change). An exploratory bet with a tight stop is not a bad idea. If it works great - if it doesn't that's what the stop is there for.
Regarding my final comment in post 2759/2760 - Put another way, highly specialised contract fermentation can apparently produce hard to replicate cannabinoids at commercial scale for consumer applications and pharmacological pipelines, which in turn, like hemp and its derivatives, will also require accurate testing in order to have accurate and appropriate consumer protection labelling, thus staying the right side of the FDA in terms of marketing and authorisation.

'Fermented' food for thought: Specialist cannabinoid production capability along with specialist authorised testing capability would appear to be very complimentary, and would thus appear to represent an attractive fit for companies producing next-generation natural ingredients.

Readers will note in post 2759 that ADL test plant material for Delta-9-THC, THCA and 9 other cannabinoids.

Looks like the chart is bottoming…
A free worthwhile, easy to read pdf -

COVID-19 Has Transformed Society: What it Means for Clinical Labs
Posted by Chris Wolski | Jun 6, 2022

Since its declaration as a pandemic in March 2020, COVID-19 has transformed society, particularly attitudes about clinical testing. Even with COVID-19 entering its endemic phase, due to a combination of scientific reality with falling infection numbers in first-world countries, political and economic pressure by citizens and business leaders, and plain, old-fashioned exhaustion, laboratorians and pathologists know that COVID-19 is here to stay no matter the societal pressures designed to “move beyond” the pandemic.

There is little doubt clinical laboratories will remain on the front lines of the fight against COVID. In this CLP-produced eBook you will learn:

How serology has played and will continue to play a key role in identifying and classifying new SARS-CoV-2 mutations, allowing new tests to be developed quickly.
How labs can help clinicians effectively meet COVID testing demands during so-called “flu season” with planning and multiplex testing options.

How clinical laboratories will play a critical role in helping clinicians identify long or chronic COVID conditions that could plague the healthcare system for decades to come.

Clinical Laboratories Remaining Vigilant
Clinical laboratories will remain on the front lines of the fight against COVID.

In the following pages you will learn:
• How serology has played and will continue to play a key role
in identifying and classifying new SARS-CoV-2 mutations,
allowing new tests to be developed quickly.
• How labs can help clinicians effectively meet COVID testing
demands during so-called “flu season” with planning and
multiplex testing options.
• How clinical laboratories will play a critical role in helping
clinicians identify long or chronic COVID conditions that
could plague the healthcare system for decades to come.

It is unclear the long-term effects that COVID will have on society as a whole, but clinical laboratories will undoubtedly continue to play a role in keeping SARS-CoV-2, at worse, an endemic annoyance.
Chris Wolski is chief editor of CLP

Good to have that exposure. Legalisation will probably involve potency limits that will need testing for. Havent read the entire post so may already have been mentioned in there.
Edit to the above post - this will not be EKF's only exposure to cannabis compounds and formulations
Long weekend so nothing to "note" from our resident gambler. What's going on - run out of batteries?
Could there be any interest in the Angle Parsortix liquid biopsy, which has just received FDA approval? If not, there should be :¬)

FDA clearance RNS:

Recent article in the FT, courtesy of ASDB9 on the Angle thread:

Pharmaceutical companies are lining up to use a pioneering cancer test developed by UK start-up Angle after it received a first-of-its-kind US regulatory clearance.

Angle's liquid biopsy test captures live cancer cells in the blood that clinicians can use to personalise treatment by understanding the mutations and gene expression in each patient's cancer. Shares in the London-listed company jumped almost 60 per cent on the day the Food and Drug Administration gave the test clearance for use in metastatic breast cancer.

The Surrey-based start-up already works with US drugmaker Abbott to use its test to identify patients who will respond to its treatment Herceptin. It is working on a trial in ovarian cancer and this week signed a deal with Philadelphia-based MidLantic Urology to study its test in prostate cancer. Andrew Newland, chief executive, said other companies had approached Angle since the clearance last week because the test enables them to follow their progress as the drug tackles tumours. Ultimately, it hopes they will develop diagnostics as companions to each drug.

Our vision is that we're going to transform the way that cancer is diagnosed and treated for every cancer type worldwide, he said. So we either have to be a very, very large company, or as we're currently planning, we have to have many deals with very large companies to achieve that. He said Angle wants to help clinicians who are flying blind, trying to work out which treatments a patient will respond to. In metastatic breast cancer, over half of patients do not have a biopsy at the secondary site, or repeat biopsies. The cancer changes over time so the tissue biopsy becomes out of date, he said. Until now, harvesting these cancer cells has been a huge challenge because there is roughly one to every billion blood cells.

The company, which grew out of a consulting business helping commercialise intellectual property, acquired the patents behind the test from George Hvichia, a scientist at the University of Pennsylvania. Investment has been pouring into the nascent liquid biopsy market, funding scientists who hope that a simple blood test can replace more invasive ways of detecting and monitoring cancer. Gene-sequencing company Illumina is acquiring cancer-testing group Grail for $8bn, while other businesses such as Thrive and Freenome have raised large sums in private funding rounds.

Rivals are focusing on developing tests that could be used to diagnose patients with early-stage cancers, before they begin to experience symptoms. This could be revolutionary but is fraught with risk because the tests must be very accurate to avoid false positives. In contrast, Angle is focusing on tracking already diagnosed cancers to enable more personalised treatment and is selling a testing product to labs rather than offering a service.

As demand soars, Angle plans to expand its workforce by 50 per cent this year and to double the size of its headquarters. But Newland said there had been far more appetite for the test in the US than from the UK's NHS, even though it has the EU CE mark. The company has worked with top UK cancer research centres such as Barts Cancer Institute but would like to roll it out more extensively across the health service, where it has been very, very difficult to gain traction. Unfortunately, we failed miserably. We tried. But we're finding all the traction is coming on the United States side, which is very disappointing, he said. We can even provide this test at relatively low cost, but it's just impossible to find anybody who's able to make a decision.

An interesting new EKF/ADL webpage -

Test Profiles (A-Z)

Only the COVID-19 test is live on the list atm, but it gives some insight into the planned expansion beyond COVID-19 testing.

Recall one of the pillars from EKF's Growth Strategy -

Investment in existing core business (enzymes and contract
manufacturing) to drive aggressive organic growth

Indicative of the level of interest and indeed the growth prospects -

QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.

BLIRT adds new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents

Strengthens QIAGEN’s sample technologies business, one of the company’s five pillars of growth, also with additional global production capacities and broader commercial reach

BLIRT develops, manufactures and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. Its offering includes proteins and enzymes that are critical to the life sciences industry and diagnostic kit manufacturers, especially for non-COVID-19 applications. BLIRT, founded in 1994 in Gdansk, Poland, has approximately 90 employees and generated 2021 sales of less than $10 million.

“The addition of BLIRT to QIAGEN brings highly complementary capabilities that will create additional growth prospects for our enzymes and reagents business,” said Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area. “BLIRT will also widen our geographic presence, add new sales channels, strengthen our production and R&D capacities and safeguard our supply chains. This acquisition will further strengthen our sample technologies business, one of our five pillars of growth. And it also supports our strategy to focus on attractive growth opportunities in the life science and molecular diagnostic markets and our disciplined approach to value-creating acquisitions.”

Full release -

EKF Diagnostics : launches middleware connectivity solution for POC analyzers and data management

EKF Diagnostics announces the launch of its newEKF Link digital connectivity solution for the secure management of point-of-care (POC) analyzers and associated data on one centralized platform. An open, flexible solution, EKF Link middleware can be interfaced to all vendors' POC analyzers, including EKF's own portfolio, to enable real-time remote management of data, such as patient test results, QC results, operator management and analyzer configuration.

"We designed EKF Link working together with hospital POC managers to ensure that our new middleware connectivity solution would meet their specific needs for a single, comprehensive and flexible platform to centrally manage all of their POC analyzers plus data generated," said Jo Nicol, Head of IT Solutions, EKF Diagnostics. "Our new EKF Link software delivers this essential digital connectivity with traceability that is increasingly required for safe, secure and effective POC testing using analyzers in many differing locations."

Full release -

Connect all of your analyzers on one software platform
EKF Link is a middleware solution for healthcare providers to manage all of their Point of Care analyzers and the generated data on one centralized platform.

EKF Link is a flexible, open solution that can be interfaced to any vendor’s Point of Care analyzer to permit the real-time management of data including patient test results, QC results, operator management and analyser configuration.

EKF Link enables the transfer of data from the analyzer to the hospital or laboratory database for subsequent processing.

I should have added that back in February, Labcorp unveiled their new Labcorp OnDemand platform (which replaced its Pixel by Labcorp service), further indicating that direct-to-consumer testing is likely to expand in terms of test types and demand, with such platforms and laboratory testing facilities also able to respond rapidly to future health emergencies.
Preparedness means being in a permanent state of readiness, for which residual stock and manufacturing capacity will from an important part.

I note that Labcorp recently obtained Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV).

It's notable because it's the first non-prescription, direct-to-consumer at-home collection PCR test kit for combined COVID-19, Flu and RSV Detection. I believe they will not be the only company to obtain such authorisation, and it's likely that companies will pursue full FDA authorisation in due course.

Test kits direct to consumers for multiple respiratory viruses beyond COVID-19 indicates the new direction of travel, and that the paradigm shift is already underway. These types of test kits and their effective use has been well and truly validated via the pandemic. it's therefore very likely that momentum (new additional direct-to-consumer test kits) will build further in this area.

EKF Diagnostics contract manufacturing facilities are well placed to benefit.

The testing tail might, unfortunately, prove to be longer than some are currently factoring in, and in any regard, countries need to be prepared in terms of readying large-scale pandemic response (and not just for COVID-19)-

U.S. Covid Hospitalizations Surge 29% In Two Weeks
Zachary Snowdon Smith Forbes Staff
I cover breaking news for Forbes.
May 26, 2022

U.S. Covid-19 hospitalizations have increased 29% over the past 14 days, according to a New York Times analysis of Department of Health and Human Services data, suggesting that a new Covid-19 surge could be underway following a roughly three-month lull.

Forty-seven states reported increased Covid-19 hospitalizations, with the largest increases recorded in Wyoming, where hospitalizations increased by 141%, in New Mexico, where they increased by 114%, and Louisiana, where they increased by 94%.

This national increase in hospitalizations was accompanied by a dramatic 31% increase in seven-day average infection rates and a 10% increase in Covid-19 deaths.

Rises in Covid-19 hospitalizations were strongly associated with rises in Covid-19 transmission—83% of states with hospitalization rate increases above the national average also reported above-average infection rate increases.

Birx warned the public to prepare for a Covid-19 surge this summer, which she predicted would hit Southern states the hardest. This prediction is consistent with the New York Times’ analysis of data from the past 14 days, which showed above-average infection rate increases in 14 of the 16 Southern states. The only exceptions were Mississippi and Oklahoma, which reported 27% and 3% infection rate increases, compared to a national average of 31%.

Full story -

Pfizer warns of ‘constant waves’ of Covid as complacency grows

Chief executive Albert Bourla launches plan to offer patented medicines at lower cost to poorer nations

Roula Khalaf, Andrew Edgecliffe-Johnson and Stephen Morris in Davos and Jamie Smyth in New York MAY 25 2022

Growing complacency about Covid-19 and politicisation of the pandemic response will cost lives as the world is hit by new waves of the virus in the coming months, Pfizer’s chief executive has warned.

Albert Bourla said people were growing “tired” of the measures introduced to slow the spread of the virus, while “politicians want to claim victory”. Compliance with authorities’ requests for people to get booster shots would fall even among those who are already vaccinated, he predicted.

This, combined with waning immunity from previous infections and vaccinations, was likely to lead to “constant waves” of Covid variants and deaths, he said.

“I feel when I discuss [Covid] with my friends, people are ready to compromise and lower the bar: maybe we can accept a few more old people dying, [rather] than have to work with a mask,” Bourla said in an interview in Davos, Switzerland, where he noted that few attendees at the World Economic Forum’s annual meeting were masked.

“What worries me is the complacency,” he said, adding that the consequences could be seen in three to six months.

Full story -

Thankfully, there has been a decoupling between infection rates and hospitalisations and deaths, so hopefully that holds. As it is becoming clearer that we will have to learn to live with COVID for the foreseeable, as opposed to it disappearing.

Mr Market non-plussed old chap. Fact am afraid. As one of the best ever in this business used to say, (except Mr Market's view) the rest is conversation. Yawn.
Above post corrected/edited
James...Yes, I had considered that too, as the average price of the recent buyback shares was 43.29 pence i.e. the current price is notably cheaper than the buyback price. However, issuing new shares negates the previously stated rationale at completion of the recent buyback that stated "Buying back this amount of ordinary shares at current levels more than offsets the dilutive effect of the new ordinary shares issued in 2021."
Nothing to stop them issuing new shares at any time under the shareholder authorisation they have if they need to do so for any reason.
The other aspect is that cancelation of the treasury shares also reflects the managements confidence in the cash generative ability of the Company in still maintaining a sound balance sheet consistent with its capital allocation. In other words, sufficient cash (current and 'future'), and high confidence in the effect from the delivery of the Growth Strategy.
So the buyback shares have been destroyed

buywell can't understand the logic of buying back 9m shares at a higher price than today to destroy them in the climate of today

Cash will be too hard to mention if inflation goes above 10% for any time

An interesting RNS today, that answers one aspect of my post above, in that the treasury shares will be cancelled as of tomorrow!

In my book that appears to imply something has changed. In other words, the previous buyback conducted in 2018 stated that "the Buy-Back will be funded from the Company's existing cash resources and any Ordinary Shares re-purchased will be cancelled." Whereas the recent buyback stated that "the Buyback will be funded from the Company's existing surplus cash resources and all Ordinary Shares purchased will be held in treasury." Implying that there may have been some strategy/intention to reissue those shares.

And further highlights the dynamic I referred to above (Harwood's 29.04% holding) making it difficult for a new buyback programme to purchase any notable quantity of shares without trigger a mandatory offer. Again unless I am missing something!

So, I therefore assume we will not see a new buyback programme anytime soon, unless perhaps any unwanted interest materialises in the wings, and there would be a preference for a safer/preferred bidder that would see though the delivery of growth strategy?

Does Anyone have any other thoughts, or experienced similar situations?

Chat Pages: Latest  180  179  178  177  176  175  174  173  172  171  170  169  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |